[ad_1]
The vaccine was also compared with Alpha and Beta variants and the original virus.
Researchers from one of Sri Lanka’s prestigious universities have discovered that China’s national drug Covid-19 vaccine is very effective against the Delta variant, which has become a major variant in the world.
“This vaccine was found to be very effective against delta variants. The antibody response to delta variants and neutralizing antibodies is similar to the level after natural infection,” the university said on its website on Monday.
According to Xinhua News Agency, according to this study, 95% of people who received two doses of Sinopharm vaccine developed antibodies similar to those naturally infected with Covid-19.
Where can Sinopharm play a booster in the UAE
According to Xinhua News Agency, the study showed that the two doses of Sinopharm vaccine produced neutralizing antibodies in 81.25% of recipients. These antibody levels were similar to those after natural Covid-19 infection.
The research team includes Sri Lankan scientists, Professor Neelika Malavige, head of the Department of Immunology and Molecular Medicine, Jayevad Napura University, Sri Lanka, her colleague Dr. Chandima Jeewandara, and Oxford University researchers Professor Graham Ogg and Professor Alain Townsend.
Professor Neelika said that due to the country’s sufficient inventory, Sinopharm is currently the most commonly used vaccine launched in Sri Lanka.
So far, 4.63 million people in Sri Lanka have received the first dose of the Covid-19 vaccine, and another 1.29 million people have received the second dose. No single case of serious side effects related to the vaccine has been reported.
Professor Malavige said that this study is the first of its kind published in the world. Experts have studied various possible angles of the immune system from the jab of the Sinopharm Group.
The vaccine was also compared with Alpha and Beta variants of the virus and the original virus.
“The conclusion of this report is that when it comes to Delta and other variants, Sinopharm’s vaccine will trigger an antibody response at a level similar to that of a naturally infected person, which is very good,” said Professor Malawige.
“In the age group 20 to 40, 98% of people developed antibodies, while in the age group over 60, 93% developed antibodies. This is not surprising, because older people respond more to vaccines. Small,” the professor added.
She said that the data of Sinopharm has not been disclosed to the world before, and such real-world data is very important for building confidence in vaccines at home and abroad.
[ad_2]
Source link